The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Protein kinases — the major drug targets of the twenty-first century?
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Diav‐Citrin, O., Atanackovic, G., & Koren, G. (1999) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199902000-00011 · Cited by 21
RetractedDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., & Nishizuka, Y. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34459-4 · Cited by 4,725
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Self-citationA protein kinase involved in the regulation of inflammatory cytokine biosynthesis
Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Keys, J. R., Land vatter, S. W., et al. (1994) · Nature · doi:10.1038/372739a0 · Cited by 3,288
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Cited by
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
The evolving role of natural products in drug discovery
Koehn, F. E., & Carter, G. T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1657 · Cited by 2,572
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Self-citationKinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
GraphDTA: predicting drug–target binding affinity with graph neural networks
Nguyen, T., Le, H., Quinn, T. P., Nguyen, T., Le, T. D., & Venkatesh, S. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa921 · Cited by 1,220
Scale-free networks in cell biology
Albert, R. (2005) · Journal of Cell Science · doi:10.1242/jcs.02714 · Cited by 1,215
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,034
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
Electrochemical Methods for the Analysis of Clinically Relevant Biomolecules
Labib, M., Sargent, E. H., & Kelley, S. O. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00220 · Cited by 976
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment
Johnson, R., & Halder, G. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4161 · Cited by 881
The emerging complexity of protein ubiquitination
Komander, D. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370937 · Cited by 821
Quantitative Phosphoproteomics Applied to the Yeast Pheromone Signaling Pathway
Gruhler, A., Olsen, J. V., Mohammed, S., Mortensen, P., Færgeman, N. J., Mann, M., & Jensen, O. N. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400219-mcp200 · Cited by 763
Hildebrandt, N., Spillmann, C. M., Algar, W. R., Pons, T., Stewart, M. H., Oh, E., Susumu, K., Díaz, S. A., Delehanty, J. B., & Medintz, I. L. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00030 · Cited by 730
Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases
Brenk, R., Schipani, A., James, D., Krasowski, A., Gilbert, I. H., Frearson, J., & Wyatt, P. G. (2008) · ChemMedChem · doi:10.1002/cmdc.200700139 · Cited by 709
Features of Selective Kinase Inhibitors
Knight, Z. A., & Shokat, K. M. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.04.011 · Cited by 657
Asati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.012 · Cited by 612
Pharmacological inhibitors of glycogen synthase kinase 3
MEIJER, L., FLAJOLET, M., & GREENGARD, P. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.07.006 · Cited by 584
Calmodulin kinase II inhibition protects against structural heart disease
Zhang, R., Khoo, M. S. C., Wu, Y., Yang, Y., Grueter, C. E., Ni, G., Price, E. E., Thiel, W., Guatimosim, S., Song, L.-S., et al. (2005) · Nature Medicine · doi:10.1038/nm1215 · Cited by 579
Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal Kinases
Bogoyevitch, M. A., & Kobe, B. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00025-06 · Cited by 573
Halogen Bonding—A Novel Interaction for Rational Drug Design?
Lu, Y., Shi, T., Wang, Y., Yang, H., Yan, X., Luo, X., Jiang, H., & Zhu, W. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9000133 · Cited by 559
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Roskoski, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 559
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Pharmacological inhibitors of cyclin-dependent kinases
Knockaert, M., Greengard, P., & Meijer, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02071-0 · Cited by 537
Reconstruction of cellular signalling networks and analysis of their properties
Papin, J. A., Hunter, T., Palsson, B. O., & Subramaniam, S. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1570 · Cited by 532
A historical overview of protein kinases and their targeted small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.010 · Cited by 526
Ward, P., Equinet, L., Packer, J., & Doerig, C. (2004) · BMC Genomics · doi:10.1186/1471-2164-5-79 · Cited by 507
Liao, J. J.-L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0608107 · Cited by 507
Metabolite concentrations, fluxes and free energies imply efficient enzyme usage
Park, J. O., Rubin, S. A., Xu, Y.-F., Amador-Noguez, D., Fan, J., Shlomi, T., & Rabinowitz, J. D. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2077 · Cited by 453
“Journal Nature chemical biology, 12(7)”
Targeting cancer with kinase inhibitors
Gross, S., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76094 · Cited by 444
Poynton, F. E., Bright, S. A., Blasco, S., Williams, D. C., Kelly, J. M., & Gunnlaugsson, T. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00680b · Cited by 421
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., & Daley, G. Q. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1486 · Cited by 411
Kindrachuk, J., Ork, B., Hart, B. J., Mazur, S., Holbrook, M. R., Frieman, M. B., Traynor, D., Johnson, R. F., Dyall, J., Kuhn, J. H., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03659-14 · Cited by 407
Indolocarbazole natural products: occurrence, biosynthesis, and biological activity
Sánchez, C., Méndez, C., & Salas, J. A. (2006) · Nat. Prod. Rep. · doi:10.1039/b601930g · Cited by 407
Why nature really chose phosphate
Kamerlin, S. C. L., Sharma, P. K., Prasad, R. B., & Warshel, A. (2013) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583512000157 · Cited by 397
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Dar, A. C., & Shokat, K. M. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090308-173656 · Cited by 388
Separation and detection of large phosphoproteins using Phos-tag SDS-PAGE
Kinoshita, E., Kinoshita-Kikuta, E., & Koike, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.154 · Cited by 386
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
Roskoski, R. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107059 · Cited by 383
Atropisomerism in Medicinal Chemistry: Challenges and Opportunities
Toenjes, S. T., & Gustafson, J. L. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0152 · Cited by 382
Polychronopoulos, P., Magiatis, P., Skaltsounis, A.-L., Myrianthopoulos, V., Mikros, E., Tarricone, A., Musacchio, A., Roe, S. M., Pearl, L., Leost, M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031016d · Cited by 380
Prospects for new antibiotics: a molecule-centered perspective
Walsh, C. T., & Wencewicz, T. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2013.49 · Cited by 372
Emerging roles of nuclear protein phosphatases
Moorhead, G. B. G., Trinkle-Mulcahy, L., & Ulke-Lemée, A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2126 · Cited by 365
Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials
Meijer, L., & Raymond, E. (2003) · ChemInform · doi:10.1002/chin.200336265 · Cited by 362
Roscovitine Targets, Protein Kinases and Pyridoxal Kinase
Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., Koken, M., Coburn, S. P., Tang, L., Jiang, T., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500806200 · Cited by 356
Oxindole: A chemical prism carrying plethora of therapeutic benefits
Kaur, M., Singh, M., Chadha, N., & Silakari, O. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.011 · Cited by 349
Isoform-selective histone deacetylase inhibitors
Bieliauskas, A. V., & Pflum, M. K. H. (2008) · Chemical Society Reviews · doi:10.1039/b703830p · Cited by 350
In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases
Patricelli, M. P., Nomanbhoy, T. K., Wu, J., Brown, H., Zhou, D., Zhang, J., Jagannathan, S., Aban, A., Okerberg, E., Herring, C., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.04.011 · Cited by 348
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Structure and regulation of Kit protein-tyrosine kinase—The stem cell factor receptor
Roskoski, R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.150 · Cited by 345
Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions
BIONDI, R. M., & NEBREDA, A. R. (2003) · Biochemical Journal · doi:10.1042/bj20021641 · Cited by 334
Src family kinases: Regulation of their activities, levels and identification of new pathways
Ingley, E. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.08.012 · Cited by 335
Strategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 334
Global Proteome Analysis of the NCI-60 Cell Line Panel
Gholami, A. M., Hahne, H., Wu, Z., Auer, F. J., Meng, C., Wilhelm, M., & Kuster, B. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.018 · Cited by 302
Halogen bonding for rational drug design and new drug discovery
Lu, Y., Liu, Y., Xu, Z., Li, H., Liu, H., & Zhu, W. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.678829 · Cited by 318
Targeting innate immunity protein kinase signalling in inflammation
Gaestel, M., Kotlyarov, A., & Kracht, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2829 · Cited by 316
Bodenmiller, B., Wanka, S., Kraft, C., Urban, J., Campbell, D., Pedrioli, P. G., Gerrits, B., Picotti, P., Lam, H., Vitek, O., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2001182 · Cited by 306
Bioactive iridium and rhodium complexes as therapeutic agents
Leung, C.-H., Zhong, H.-J., Chan, D. S.-H., & Ma, D.-L. (2013) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2013.01.034 · Cited by 303
A historical perspective on porphyrin-based metal–organic frameworks and their applications
Zhang, X., Wasson, M. C., Shayan, M., Berdichevsky, E. K., Ricardo-Noordberg, J., Singh, Z., Papazyan, E. K., Castro, A. J., Marino, P., Ajoyan, Z., et al. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213615 · Cited by 300
KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space
van Linden, O. P. J., Kooistra, A. J., Leurs, R., de Esch, I. J. P., & de Graaf, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400378w · Cited by 298
Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies
Widmer, N., Bardin, C., Chatelut, E., Paci, A., Beijnen, J., Levêque, D., Veal, G., & Astier, A. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.015 · Cited by 296
Evidence that Monastrol Is an Allosteric Inhibitor of the Mitotic Kinesin Eg5
Maliga, Z., Kapoor, T. M., & Mitchison, T. J. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00212-0 · Cited by 293
Selectively Nonselective Kinase Inhibition: Striking the Right Balance
Morphy, R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901132v · Cited by 292
Large-Scale Phosphorylation Analysis of α-Factor-Arrested Saccharomyces cerevisiae
Li, X., Gerber, S. A., Rudner, A. D., Beausoleil, S. A., Haas, W., Villén, J., Elias, J. E., & Gygi, S. P. (2007) · Journal of Proteome Research · doi:10.1021/pr060559j · Cited by 290
Phosphate Recognition in Structural Biology
Hirsch, A. K. H., Fischer, F. R., & Diederich, F. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200603420 · Cited by 287
Rask-Andersen, M., Masuram, S., & Schiöth, H. B. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135943 · Cited by 282
Wang, Z., Lévy, R., Fernig, D. G., & Brust, M. (2006) · Journal of the American Chemical Society · doi:10.1021/ja058135y · Cited by 276
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Roskoski, R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106552 · Cited by 273
ADP-Glo: A Bioluminescent and Homogeneous ADP Monitoring Assay for Kinases
Zegzouti, H., Zdanovskaia, M., Hsiao, K., & Goueli, S. A. (2009) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2009.0222 · Cited by 273
Drugs for Allosteric Sites on Receptors
Wenthur, C. J., Gentry, P. R., Mathews, T. P., & Lindsley, C. W. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134525 · Cited by 273
Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases?
Cohen, P., & Tcherpakov, M. (2010) · Cell · doi:10.1016/j.cell.2010.11.016 · Cited by 271
Self-citationPTP1B inhibitors as potential therapeutics in the treatment of Type 2 diabetes and obesity
Zhang, Z.-Y., & Lee, S.-Y. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.2.223 · Cited by 271
Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
Workman, P., Clarke, P. A., Raynaud, F. I., & van Montfort, R. L. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4355 · Cited by 264
A conserved protonation-dependent switch controls drug binding in the Abl kinase
Shan, Y., Seeliger, M. A., Eastwood, M. P., Frank, F., Xu, H., Jensen, M. Ø., Dror, R. O., Kuriyan, J., & Shaw, D. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811223106 · Cited by 262
COPD: current therapeutic interventions and future approaches
Barnes, P. J., & Stockley, R. A. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00139104 · Cited by 259
Protein kinase inhibitors: contributions from structure to clinical compounds
Johnson, L. N. (2009) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004745 · Cited by 256
Engineering Nanocomposite Materials for Cancer Therapy
Minelli, C., Lowe, S. B., & Stevens, M. M. (2010) · Small · doi:10.1002/smll.201000523 · Cited by 255
Young, W., Russell, S. V., Robinson, C. A., & Barkemeyer, R. (2017) · Resources, Conservation and Recycling · doi:10.1016/j.resconrec.2016.10.016 · Cited by 216
Liu, G., Gu, B., He, X.-P., Joshi, R. B., Wackerle, H. D., Rodriguiz, R. M., Wetsel, W. C., & McNamara, J. O. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.027 · Cited by 210
Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases
Patterson, H., Nibbs, R., McInnes, I., & Siebert, S. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12248 · Cited by 199
p38MAPK plays a crucial role in stromal-mediated tumorigenesis
Alspach, E., Flanagan, K. C., Luo, X., Ruhland, M. K., Huang, H., Pazolli, E., Donlin, M. J., Marsh, T., Piwnica-Worms, D., Monahan, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0743 · Cited by 167
Advances in small molecules promoting neurotrophic function
PRICE, R., MILNE, S., SHARKEY, J., & MATSUOKA, N. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.005 · Cited by 148
Roscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1
Oumata, N., Bettayeb, K., Ferandin, Y., Demange, L., Lopez-Giral, A., Goddard, M.-L., Myrianthopoulos, V., Mikros, E., Flajolet, M., Greengard, P., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800109e · Cited by 139
Selectivity of Docking Sites in MAPK Kinases
Bardwell, A. J., Frankson, E., & Bardwell, L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900080200 · Cited by 127
Emerging role of MAP kinase pathways as therapeutic targets in COPD
Mercer, B. A., & D'Armiento, J. M. (2006) · International Journal of COPD · doi:10.2147/copd.2006.1.2.137 · Cited by 118
Large-scale cytological profiling for functional analysis of bioactive compounds
Woehrmann, M. H., Bray, W. M., Durbin, J. K., Nisam, S. C., Michael, A. K., Glassey, E., Stuart, J. M., & Lokey, R. S. (2013) · Molecular BioSystems · doi:10.1039/c3mb70245f · Cited by 62
Robey, R. W., Shukla, S., Steadman, K., Obrzut, T., Finley, E. M., Ambudkar, S. V., & Bates, S. E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0811 · Cited by 61
Tiziani, S., Kang, Y., Choi, J. S., Roberts, W., & Paternostro, G. (2011) · Nature Communications · doi:10.1038/ncomms1562 · Cited by 60
Kholodenko, B. N. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.014 · Cited by 49
van Rhijn, N., Zhao, C., Al-Furaiji, N., Storer, I. S. R., Valero, C., Gago, S., Chown, H., Baldin, C., Grant, R.-F., Bin Shuraym, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48592-8 · Cited by 30
D’Incal, C., Broos, J., Torfs, T., Kooy, R. F., & Vanden Berghe, W. (2022) · Cells · doi:10.3390/cells11081325 · Cited by 29
NMR Spectroscopic Investigations of the Activated p38α Mitogen‐Activated Protein Kinase
Nielsen, G., & Schwalbe, H. (2011) · ChemBioChem · doi:10.1002/cbic.201100527 · Cited by 15
Hepatotoxicity of FDA-approved small molecule kinase inhibitors
Jiang, H., Jin, Y., Yan, H., Xu, Z., Yang, B., He, Q., & Luo, P. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1867104 · Cited by 13
Computational studies on the functional and structural impact of pathogenic mutations in enzymes
Dissanayake, U. C., Roy, A., Maghsoud, Y., Polara, S., Debnath, T., & Cisneros, G. A. (2025) · Protein Science · doi:10.1002/pro.70081 · Cited by 8
Unsupervised learning reveals landscape of local structural motifs across protein classes
(2025) · doi:10.1093/bioinformatics/btaf377 · Cited by 2
Metadata
- Authors
- Cohen, P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-04
- Volume
- 1
- Issue
- 4
- Pages
- 309-315
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2138778824
- Cited by
- 2,186
- References
- 70
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.